Today, we develop, manufacture and bring to market safe, innovative and cost-effective pharmaceuticals that help improve patient quality of life.  Par Pharmaceutical offers a line of high barrier-to-entry generic drugs, while Par Specialty Pharmaceuticals provides niche, innovative brands.  Par Sterile Products develops, manufactures and markets both branded and generic aseptic injectable pharmaceuticals.


2015

  • Par acquires Ethics Bio Lab Pvt. Ltd., an India-based contract research organization that conducts bioavailability, bioequivalence, pharmacokinetic and clinical endpoint studies
  • Par acquires Innoteq, Inc., a developer and manufacturer of innovative coated products, including orally-dissolving thin films and transdermal patches

2014

  • Par receives FDA approval of Vasostrict® (vasopressin injection, USP), the first and only vasopressin injection, USP, product with an NDA approved by the FDA
  • Par opens a business office in London to serve as its initial point of entry into the European generics markets
  • Par receives FDA approval of Nascobal® (Cyanocobalamin, USP) Nasal Spray single-use device
  • Terrance J. Coughlin is named Chief Operating Officer of Par Pharmaceutical, Inc.
  • Antonio R. Pera is named Chief Commercial Officer of Par Pharmaceutical, Inc.
  • Par acquires JHP Pharmaceuticals, a developer, manufacturer and marketer of branded and generic aseptic injectable products

2012

  • Par acquires 14 generic products from Watson Pharmaceutical and Actavis Group
  • Paul V. Campanelli is named Chief Executive Officer of Par Pharmaceutical Companies, Inc.
  • Par is acquired by TPG, a leading global private investment firm with $65 billion of capital under management
  • Par Formulations (formerly Edict Pharmaceuticals) receives its first Abbreviated New Drug Application (ANDA) approval
  • Par acquires Edict Pharmaceuticals Pvt. Ltd., an India-based developer and manufacturer of generic pharmaceuticals

2011

  • Par acquires Anchen Pharmaceuticals, a developer, manufacturer and marketer of extended-release generic products
  • Par acquires three generic products from Teva Pharmaceuticals

2009

  • Par acquires worldwide rights to Nascobal® (cyanocobalamin, USP) Nasal Spray from QOL Medical and relaunches the product

2005

  • Par receives FDA approval and launches its first branded product, Megace® ES* (megestrol acetate)

1987

  • Par Pharmaceutical Companies, Inc. (PRX) is listed on the New York Stock Exchange

1984

  • Following an initial public offering, Par Pharmaceutical is listed on the American Stock Exchange

1978

  • Par Pharmaceutical is founded as a developer, manufacturer and marketer of generic pharmaceuticals

* Par licensed the Megace® name from Bristol-Myers Squibb Company